{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Bionano Genomics, Inc.
Bionano Genomics Hits 52-Week Low at $1.50 Amidst Major Decline
Bionano Genomics, Inc. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. With a market capitalization of approximately USD 20 million, the company faces financial challenges, including negative return on equity and a low price-to-book ratio, despite some operational improvements.
Is Bionano Genomics, Inc. technically bullish or bearish?
As of April 11, 2025, the market trend is mildly bearish, influenced by daily moving averages and Bollinger Bands, despite some mildly bullish signals from the weekly MACD and KST.
Who are in the management team of Bionano Genomics, Inc.?
As of March 2022, Bionano Genomics, Inc.'s management team includes Dr. David Barker (Independent Chairman), Dr. R. Erik Holmlin (President and CEO), and several directors, including Dr. Yvonne Linney, Ms. Hannah Mamuszka, Dr. Albert Luderer, Mr. Christopher Twomey, and Dr. Kristiina Vuori, reflecting a diverse leadership structure.
What does Bionano Genomics, Inc. do?
Bionano Genomics, Inc. is a life sciences company focused on genome analysis, with a market cap of approximately $10.97 million and reported net sales of $6 million but a net loss of $3 million for Q1 2025. The company has no dividend yield and negative return on equity.
How big is Bionano Genomics, Inc.?
As of Jun 18, Bionano Genomics, Inc. has a market capitalization of 10.97 million and reported net sales of 28.46 million with a net profit of -83.69 million over the last four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
